Regeneron Pharmaceuticals (REGN) is back in focus after expanding its cancer research partnership with CytomX Therapeutics and reporting early clinical results for Lynozyfic in light chain amyloidosis, which together have supported fresh interest in the stock.

Despite the positive reaction to the CytomX expansion and Lynozyfic data, Regeneron’s 1-day share price return of 1.58% sits against a year-to-date share price decline of 19.01%. The 1-year total shareholder return of 30.87% reflects earlier strength now giving way to softer recent momentum.

If you are watching how biotech pipelines can move stocks, it is a good time to widen the search using a screener focused on 40 healthcare AI stocks

With Regeneron trading at US$628.73 and an intrinsic value estimate that implies a 71.6% discount, alongside a 32.5% gap to the average analyst target, you have to ask: is this a genuine opportunity, or is the market already baking in future growth?

Most Popular Narrative: 28.2% Undervalued

Regeneron’s fair value in the most followed narrative sits at $875.31 versus the last close of $628.73, framing a sizeable valuation gap driven by long term pipeline expectations.

Regeneron's broad and advancing pipeline, including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity, positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.

Curious what sits behind that premium to current pricing? The narrative leans on a specific mix of revenue expansion, margin assumptions, and a higher future earnings multiple. The exact blend of growth, profitability, and discount rate inputs might surprise you. If you want to see how those moving parts combine into that $875.31 figure, the full narrative lays it out in detail.

Result: Fair Value of $875.31 (UNDERVALUED)

However, this upside story still leans heavily on EYLEA in a competitive, pricing sensitive market, and on high R&D spend that may not always translate into commercially successful drugs.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment divided between recent price action and longer term potential, it makes sense to look at the numbers yourself and decide quickly where you stand. To see what investors view as the key upsides before you firm up your own stance, check out the 4 key rewards

Looking for more investment ideas?

If you stop here, you risk missing other stocks that might fit your style even better, so take a few minutes and broaden your watchlist with focused screeners.

• Spot potential value opportunities early by scanning 47 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect them yet.
• Prioritise resilience by reviewing 65 resilient stocks with low risk scores that score well on financial health and lower overall risk profiles.
• Get ahead of the crowd by searching a screener containing 22 high quality undiscovered gems that are not widely followed but still show solid underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.